Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- IMMU.ST
- Price
- 8.46
- Stock movement down
- -0.21 (-2.42%)
- Company name
- Mendus AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 426.14M
- Ent verdi
- 361.05M
- Pris/omsetning
- 13.36
- Pris/bok
- 0.63
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -29.42%
- 1 års avkastning
- -26.03%
- 3 års avkastning
- -48.84%
- 5 års avkastning
- -46.78%
- 10 års avkastning
- -30.70%
Sist oppdatert: 2024-12-21
UTBYTTE
IMMU.ST betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 13.36 |
| Pris til bok | 0.63 |
| EV i forhold til salg | 11.32 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 50.36M |
| EPS (TTM) | -2.76 |
| FCF per aksje (TTM) | -1.46 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 31.90M |
| Bruttofortjeneste (TTM) | 26.60M |
| Driftsinntekter (TTM) | -145.19M |
| Netto inntekt (TTM) | -138.05M |
| EPS (TTM) | -2.76 |
| EPS (1 år fremover) | -0.49 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 83.38% |
| Driftsmargin (TTM) | -455.20% |
| Fortjenestemargin (TTM) | -432.81% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 109.32M |
| Netto fordringer | 0.00 |
| Samlede omløpsmidler | 156.78M |
| Goodwill | 108.35M |
| Immaterielle eiendeler | 424.09M |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 719.92M |
| Leverandørgjeld | 5.67M |
| Kortsiktig/nåværende langsiktig gjeld | 22.46M |
| Sum kortsiktig gjeld | 23.59M |
| Sum gjeld | 44.23M |
| Aksjonærenes egenkapital | 675.69M |
| Netto varige driftsmidler | 0.00 |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -69.96M |
| Kapitalutgifter (TTM) | 3.29M |
| Fri kontantstrøm (TTM) | -73.24M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -20.43% |
| Avkastning på eiendeler | -19.18% |
| Avkastning på investert kapital | -20.35% |
| Kontantavkastning på investert kapital | -10.80% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 8.36 |
| Daglig høy | 9.00 |
| Daglig lav | 8.14 |
| Daglig volum | 29K |
| Tidenes høyeste | 738.72 |
| 1 år analytikerestimat | 21.50 |
| Beta | 0.82 |
| EPS (TTM) | -2.76 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 13 Feb 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| IMMU.ST | S&P500 | |
| Nåværende prisfall fra toppnotering | -98.85% | -2.74% |
| Høyeste prisfall | -99.94% | -56.47% |
| Dato for høyeste fall | 29 May 2024 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -67.76% | -11.13% |
| Gj.snittlig tid til ny topp | 128 days | 12 days |
| Maks tid til ny topp | 2293 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
426.14M
Markedsverdi kategori
Small-cap
Beskrivelse
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company has a collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Ansatte
30
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Sweden
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as...
17. desember 2024
Mendus AB (STU:1YG0) reports significant progress in clinical trials and manufacturing alliances, despite a Q3 net loss of 23 million.
9. november 2024
Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present t...
19. mars 2024
Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 p...
15. mars 2024
Press Release Stockholm, Sweden, March 15, 2024 On June 8, 2023, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU), announced that the Board of Directors had resolved on a capital...
15. mars 2024
Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemiaRegistration trial preparatio...
12. mars 2024
Press release Stockholm, Sweden, February 27, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will ...
27. februar 2024
Press Release Stockholm, Sweden, February 23, 2024 Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discu...
23. februar 2024
Press Release Stockholm, Sweden, February 14, 2024 Positive ADVANCE II data at ASH caps strong 2023 The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to f...
14. februar 2024
Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same...
9. februar 2024
Neste side